Literature DB >> 27718463

Simultaneous quantification of soman and VX adducts to butyrylcholinesterase, their aged methylphosphonic acid adduct and butyrylcholinesterase in plasma using an off-column procainamide-gel separation method combined with UHPLC-MS/MS.

Chang-Cai Liu1, Gui-Lan Huang1, Hai-Ling Xi2, Shi-Lei Liu3, Jing-Quan Liu4, Hui-Lan Yu4, Shi-Kun Zhou1, Long-Hui Liang4, Ling Yuan4.   

Abstract

This work describes a novel and sensitive non-isotope dilution method for simultaneous quantification of organophosphorus nerve agents (OPNAs) soman (GD) and VX adducts to butyrylcholinesterase (BChE), their aged methylphosphonic acid (MeP) adduct and unadducted BChE in plasma exposed to OPNA. OPNA-BChE adducts were isolated with an off-column procainamide-gel separation (PGS) from plasma, and then digested with pepsin into specific adducted FGES*AGAAS nonapeptide (NP) biomarkers. The resulting NPs were detected by UHPLC-MS/MS MRM. The off-column PGS method can capture over 90% of BChE, MeP-BChE, VX-BChE and GD-BChE from their respective plasma materials. One newly designed and easily synthesized phosphorylated BChE nonapeptide with one Gly-to-Ala mutation was successfully reported to serve as internal standard instead of traditional isotopically labeled BChE nonapeptide. The linear range of calibration curves were from 1.00-200ngmL-1 for VX-NP, 2.00-200ngmL-1 for GD-NP and MeP-NP (R2≥0.995), and 3.00-200ngmL-1 for BChE NP (R2≥0.990). The inter-day precision had relative standard deviation (%RSD) of <8.89%, and the accuracy ranged between 88.9-120%. The limit of detection was calculated to be 0.411, 0.750, 0.800 and 1.43ngmL-1 for VX-NP, GD-NP, MeP-NP and BChE NP, respectively. OPNA-exposed quality control plasma samples were characterized as part of method validation. Investigation of plasma samples unexposed to OPNA revealed no baseline values or interferences. Using the off-column PGS method combined with UHPLC-MS/MS, VX-NP and GD-NP adducts can be unambiguously detected with high confidence in 0.10ngmL-1 and 0.50ngmL-1 of exposed human plasma respectively, only requiring 0.1mL of plasma sample and taking about four hours without special sample preparation equipment. These improvements make it a simple, sensitive and robust PGS-UHPLC-MS/MS method, and this method will become an attractive alternative to immunomagnetic separation (IMS) method and a useful diagnostic tool for retrospective detection of OPNA exposure with high confidence. Furthermore, using the developed method, the adducted BChE levels from VX and GD-exposed (0.10-100ngmL-1) plasma samples were completely characterized, and the fact that VX being more active and specific to BChE than GD was re-confirmed.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BChE adduct; Chemical warfare agent; MS; OPNA exposure; Organophosphorus nerve agents; Retrospective detection; UHPLC-ESI-MS

Mesh:

Substances:

Year:  2016        PMID: 27718463     DOI: 10.1016/j.jchromb.2016.09.044

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  On-substrate Enzymatic Reaction to Determine Acetylcholinesterase Activity in Whole Blood by Paper Spray Mass Spectrometry.

Authors:  Daniel O Carmany; Phillip M Mach; Gabrielle M Rizzo; Elizabeth S Dhummakupt; Ethan M McBride; Jennifer W Sekowski; Bernard Benton; Paul S Demond; Michael W Busch; Trevor Glaros
Journal:  J Am Soc Mass Spectrom       Date:  2018-10-02       Impact factor: 3.109

2.  Purification of recombinant human butyrylcholinesterase on Hupresin®.

Authors:  Oksana Lockridge; Emilie David; Lawrence M Schopfer; Patrick Masson; Xavier Brazzolotto; Florian Nachon
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-10-25       Impact factor: 3.205

3.  Identification and Study of Biomarkers from Novichok-Inhibited Butyrylcholinesterase in Human Plasma.

Authors:  Woo-Hyeon Jeong; Jin-Young Lee; Kyoung-Chan Lim; Hyun-Suk Kim
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.